Lenk, L., Baccelli, I., Laqua, A., Heymann, J., Reimer, C., Dietterle, A., . . . Schewe, D. M. (2024). The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis. Blood, 143(26), . https://doi.org/10.1182/blood.2023021088
Chicago Style (17th ed.) CitationLenk, Lennart, et al. "The IL-7R Antagonist Lusvertikimab Reduces Leukemic Burden in Xenograft ALL via Antibody-dependent Cellular Phagocytosis." Blood 143, no. 26 (2024). https://doi.org/10.1182/blood.2023021088.
MLA (9th ed.) CitationLenk, Lennart, et al. "The IL-7R Antagonist Lusvertikimab Reduces Leukemic Burden in Xenograft ALL via Antibody-dependent Cellular Phagocytosis." Blood, vol. 143, no. 26, 2024, https://doi.org/10.1182/blood.2023021088.
Warning: These citations may not always be 100% accurate.